Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Non-Current Debt (2021 - 2024)

Inmune Bio (INMB) has disclosed Non-Current Debt for 4 consecutive years, with $2.5 million as the latest value for Q3 2024.

  • Quarterly Non-Current Debt rose 5.22% to $2.5 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Sep 2024, up 5.22% year-over-year, with the annual reading at $9.7 million for FY2022, 32.93% down from the prior year.
  • Non-Current Debt hit $2.5 million in Q3 2024 for Inmune Bio, down from $5.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $14.6 million in Q2 2022 to a low of $2.4 million in Q3 2023.
  • Historically, Non-Current Debt has averaged $9.5 million across 4 years, with a median of $9.7 million in 2022.
  • Biggest five-year swings in Non-Current Debt: tumbled 80.41% in 2023 and later rose 5.22% in 2024.
  • Year by year, Non-Current Debt stood at $14.5 million in 2021, then plummeted by 32.93% to $9.7 million in 2022, then tumbled by 75.5% to $2.4 million in 2023, then rose by 5.22% to $2.5 million in 2024.
  • Business Quant data shows Non-Current Debt for INMB at $2.5 million in Q3 2024, $5.0 million in Q2 2024, and $7.5 million in Q1 2024.